- Home
- ONDS vs ALDX Comparison
ONDS vs ALDX Comparison
Compare ONDS & ALDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ONDS
- ALDX
- Stock Information
- Founded
- ONDS 2014
- ALDX 2004
- Country
- ONDS United States
- ALDX United States
- Employees
- ONDS N/A
- ALDX N/A
- Industry
- ONDS Telecommunications Equipment
- ALDX Biotechnology: Pharmaceutical Preparations
- Sector
- ONDS Telecommunications
- ALDX Health Care
- Exchange
- ONDS Nasdaq
- ALDX Nasdaq
- Market Cap
- ONDS 326.8M
- ALDX 270.7M
- IPO Year
- ONDS N/A
- ALDX 2014
- Fundamental
- Price
- ONDS $1.84
- ALDX $5.07
- Analyst Decision
- ONDS Strong Buy
- ALDX Strong Buy
- Analyst Count
- ONDS 2
- ALDX 2
- Target Price
- ONDS $3.25
- ALDX $9.50
- AVG Volume (30 Days)
- ONDS 20.1M
- ALDX 1.2M
- Earning Date
- ONDS 08-13-2025
- ALDX 08-04-2025
- Dividend Yield
- ONDS N/A
- ALDX N/A
- EPS Growth
- ONDS N/A
- ALDX N/A
- EPS
- ONDS N/A
- ALDX N/A
- Revenue
- ONDS $10,815,867.00
- ALDX N/A
- Revenue This Year
- ONDS $243.35
- ALDX N/A
- Revenue Next Year
- ONDS $118.81
- ALDX N/A
- P/E Ratio
- ONDS N/A
- ALDX N/A
- Revenue Growth
- ONDS N/A
- ALDX N/A
- 52 Week Low
- ONDS $0.54
- ALDX $1.14
- 52 Week High
- ONDS $3.40
- ALDX $7.20
- Technical
- Relative Strength Index (RSI)
- ONDS 47.75
- ALDX 64.20
- Support Level
- ONDS $2.02
- ALDX $5.12
- Resistance Level
- ONDS $2.20
- ALDX $5.66
- Average True Range (ATR)
- ONDS 0.24
- ALDX 0.31
- MACD
- ONDS -0.05
- ALDX -0.05
- Stochastic Oscillator
- ONDS 12.59
- ALDX 58.88
About ONDS Ondas Holdings Inc.
Ondas Holdings Inc designs, develops, manufactures, sells, and supports FullMAX Software Defined Radio (SDR) technology in the United States, Israel, and India. The company operates in two business segments namely Ondas Networks and Ondas Autonomous Systems. The company generates maximum revenue from Ondas Autonomous Systems through the sales of the Optimus system and separately priced support, maintenance, and ancillary services related to the sale of the Optimus system.
About ALDX Aldeyra Therapeutics Inc.
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.